MedTrace Logo

Exisulind Versus Placebo After Surgical Removal of the Prostate

NCT00166426 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2009-11-16

No results posted yet for this study

Summary

This is a study in which patients with prostate cancer treated by surgical removal of the prostate and considered to be at risk for prostate cancer recurrence will receive Exisulind 250 mg twice a day or placebo twice a day for two years.

Conditions

  • Prostatic Neoplasms

Interventions

DRUG

Exisulind

Sponsors & Collaborators

  • OSI Pharmaceuticals

    collaborator INDUSTRY

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Bradley C. Leibovich, M.D. · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2007-05-31
Completion
2008-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00166426 on ClinicalTrials.gov